Clinical Trial

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants.
Protocol Amendment History 4 changes
notable Enrollment increased: 74 -> 92 participants 2026-08-08
minor Trial arms changed: 5 -> 6 2026-08-08
notable Primary completion pushed: 2026-03 -> 2026-12 2026-08-08
minor Completion pushed: 2026-03 -> 2026-12 2026-08-08
Trial Details
NCT Number NCT07156201
Lead Sponsor Actio Biosciences, Inc.
Conditions KCNT1-Related Epilepsy
Enrollment 92 participants
Start Date 2025-08-28
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-07